Advances in cannabinoid receptor 1 antagonistic effect in obesity

Abstract

Abstract: Obesity which is harmful to human health has become epidemic all over the world.Nowadays, it is reported that cannabinoid receptor 1(CB1-R) is significantly associated with obesity.CB1-R belongs to g-protein coupled receptors(GPCRs).Its distribution and genetic structure have been identefied.Recently it is reported that CB1-R antagonist can regulate energy metabolism and reduce body weight through central and peripherial gateways.Meanwhile, it is helpful in treating alcohol, tobacco and drug addiction.At present, rimonabant (SR141716) has already been applied to phase III clinical trial and it can effectively reduce body weight without causing serious adverse effects.Therefore, CB1-R antagonist can be a better choice for treating obesity in the near future.

Key words: cannabinoid receptor 1, obesity, antiobesity action, drug addiction

CLC Number:

PANG Xiao-yi, DONG Zhi, FU Jie-min. Advances in cannabinoid receptor 1 antagonistic effect in obesity[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 606-609.

References

1 Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M.The endocannabinoid system:physiology and pharmacology[J].Alcohol Alcohol, 2005;40:2-14
2 Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ.Cannabinoid physiology and pharmacology:30 years of progress[J].Neuropharmacology, 2004;47:345-58
3 Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake[J].Nature, 2000; 404:661-71
4 Park B, Gibbons HM, Mitchell MD, Glassa M.Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta[J].Placenta, 2003;24:473-8
5 邹大进, 王淼.CB1-R 在治疗代谢综合症中的作用[J].世界临床药物, 2005;26:360-3
6 ElphickMR, Egertova M.The neurobiology and evolution of cannabinoid signalling[J].Philos Trans R Soc Lond B Biol Sci, 2001;356:381-408
7 Labib M.The investigation and management of obesity [J].J Clin Plthol, 2003;56:17-25
8 Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, le Fur G, Oury-Donat F, et al.The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of bbese fa fa rats and in cultured adipocyte cells[J].Mol Pharmacol, 2003;63:908-14
9 Tucci SA, Rogers EK, Korbonits M, Kirkham TC.The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin[J].Br J Pharmacol, 2004; 143:520-3
10 Verty AN, SinghME, McGregor IS, Mallet PE.The cannabinoid receptor antagonist SR141716 attenuates overfeeding induced by systemic or intracranial morphine [J].Psychopharmacology, 2003;168:314-23
11 Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos GG.The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus [J].Eur J Pharmacol, 2001;426:R3-4
12 Poirier B, Bidouard JP, Cadrouvele C, Marmiquet X, Staels B, O'Connor SE, et al.The anti-obesity effect of rimonabant is associated with an improved serum lipid profile[J].Diabetes Obes Metab, 2005;7:65-72
13 Liu YL, Connoley IP, Wilson CA, Stock MJ.Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep (ob) Lep (ob) mice[J].Int J Obes (Lond), 2005;29:183-7
14 Pertwee RG.Cannabinoids and the gastrointestinal tract[J]. Gut, 2001;48:859-67
15 Storr M, Sibaev A, Marsicano G, Lutz B, Schusdziarra V, Timmermans JP, et al.Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon[J].Mol Pharmacol, 2003;63:908-14
16 Carai MA, Colombo G, Gessa GL.Rapid tolerance to the intestinal prokinetic effect of cannabinoid CB1 receptor antagonist, SR141716(Rimonabant) [J].Eur J Pharmacol, 2004;494:221-4
17 Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, et al.The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance[J].FASEB J, 2005;19:1567-9
18 Weyer C, Funahashit, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al.Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia [J].J Clin Endocrinol Metab, 2001;86:1930-5
19 Carai MA, Colombo G, Gessa GL.Rimonabant:the first therapeutically relevant cannbinoid antagonist[J].Life Sci, 2005; 23;77:2339-50
20 Beardsley PM, Thomas BF.Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders[J].Behav Pharmacol, 2005;16:275-96
21 Daniela C, Stephen CW.The role of the endocannabinoid system in the regulation of energy homeostasis [J].Current Opinion in Endocrinology &Diabetes, 2005;12:338-51

[1]	GUO Yixun, GUAN Xiaoyin, WANG Bo, WEI Yingda, ZHANG Yan, LIN Jianhua. Research progress on pathogenesis and potential therapeutic target of sarcopenia obesity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 341-346.
[2]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[3]	MA Yitong, MA Jianhong, GAO Yating, LIU Chang. Pathogenic mechanism and research progress of adipocytokines in endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1315-1320.
[4]	ZHAO Qian, YANG Guang, CAO Lihua, YU Chenbao. CNR1 genetic variation influences the clinical outcomes of early stage type 2 diabetes mellitus treated with liraglutide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 182-188.
[5]	YUAN Lijialong, QIN Xuping. ATP synthase beta subunit function and disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 464-470.
[6]	SHEN Ji-zhong, LIU Hang. Experimental study of a metabolic syndrome mouse model induced by high sucrose-containing drinking water [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1011-1015.
[7]	CHEN Zi-miao,WANG Mei-rong,YE Ting-ting,GU Xue-jiang CHEN Xiong, ZHU Hong, NI Lian-song. Antiobesity effect of ketotifen in high-carbon hydrate-fat diet induced obese rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 23-28.
[8]	LIU Jing, SUN Ning-ling, YANG Song-na, MA Zhi-yi, YANG Jing. Effects of orlistat on endothelium-independent vasodilation function in obese subjects with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(9): 1061-1064.
[9]	WU Guan-zhong, GUO Yong-qi, SU Xin, YANG Hong-xia, ZHANG Jian. Studies on the antiobesity action and mechanisms of daidzein derivative:LRXH609 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(5): 519-523.
[10]	CUI Ming-xia, WANG Lei, ZHANG Bao-lai, LU Li, WANG Li, ZHENG Rong-liang, WUYong-jie. Establishment of diabetic obese rat model and the therapeutic effects of sibutramine on it [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(12): 1325-1329.
[11]	LIU Ying-zi, Vural Ozdemir, OUYANG Dong-sheng, LIU Zhao-qian, LIU ie, LI Zhi,WANG Dan, ZENG Fei-yue, TAN Zhi-rong, HU Dong-li, ZHOU Hong-hao. Differential effects of PPARγligand rosiglitazone and selective antagonist GW9662 on adipocytokine gene expression in 3T3-L1 adipocytes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(10): 1157-1162.
[12]	CHEN Guang-Liang, LI Li, YAN Shang-Xue, HUANG De-Wu. Anti-obesity effect of sibutramine hydrochloride in alimentary obesity rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(1): 55-58.
[13]	WANG Hui, CHEN Bing. Weight relief of sibutramine in treatment of obesity with different body weight [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(4): 327-330.
[14]	WANG Ping-Fang, YANG Ya, LIAO Er-Yuan, YAN Xiang, ZHANG Hong, HE Lin, ZHU Xue-Ping. Effect of sibutramine on the obesity with metabolic disorder of blood glu-cose and lipid [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(3): 224-230.
[15]	LIU Zhao Fang, HUANG Bin-Hui, ZHANG He. Effect of insulin intravenous infusion during operation on glucose metaboism in obese woman patients with insulin resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1999, 4(4): 296-298.